In 2012 was created Syncona Partners LLP, which is appeared as VC. The venture was found in Europe in United Kingdom. The main office of represented VC is situated in the London.
The overall number of key employees were 11.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Syncona Partners LLP, startups are often financed by UCL Technology Fund, Sixth Element Capital, Woodford Investment Management. The meaningful sponsors for the fund in investment in the same round are UCL Technology Fund, UCLB, Sixth Element Capital. In the next rounds fund is usually obtained by Woodford Investment Management, UCL Technology Fund, Sequoia Capital.
Considering the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2019. This Syncona Partners LLP works on 17 percentage points less the average amount of lead investments comparing to the other organizations. The typical startup value when the investment from Syncona Partners LLP is 50-100 millions dollars. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year.
The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Biopharma. Among the most popular portfolio startups of the fund, we may highlight Gyroscope Therapeutics, Cambridge Epigenetix, Quell Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
Related Funds
Fund Name | Location |
Akana by Perforce | Minneapolis, Minnesota, United States |
Chasing Value Asset Management | - |
Conversion Capital | New York, New York, United States |
Dada Entertainment | New York, New York, United States |
Darling Ventures | California, San Francisco, United States |
Global Health Innovative Technology Fund | Karachi, Pakistan, Sindh |
Mantella Venture Partners | Canada, Ontario, Toronto |
Nazem and Company | New York, New York, United States |
Peterson Ventures | Salt Lake City, United States, Utah |
Pixta | Japan, Tokyo |
Quasar Builders | Argentina, Buenos Aires, Distrito Federal |
Rice Warner | - |
Sanmei Touzi | China, Guangdong, Guangzhou |
SVIC | Japan, Shizuoka, Shizuoka Prefecture |
SWFI | Las Vegas, Nevada, United States |
Tiny VC | California, San Francisco, United States |
Vertex Partners | Japan, Tokyo |
Zhejiang Culture Industry Growth Fund | - |
Zoho | California, Pleasanton, United States |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Purespring Therapeutics | 09 Oct 2024 | London, England, United Kingdom | |||
Resolution Therapeutics | 03 Oct 2024 | London, England, United Kingdom | |||
Yellowstone Biosciences | $22M | 20 Jun 2024 | Oxford, Oxfordshire, United Kingdom | ||
Beacon Therapeutics | $170M | 03 Jun 2024 | London, England, United Kingdom | ||
Beacon Therapeutics | $131M | 12 Jun 2023 | London, England, United Kingdom | ||
Mosaic Therapeutics | $28M | 04 Apr 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
SwanBio Therapeutics | $56M | 18 May 2022 | Lower Merion Township, Pennsylvania, United States | ||
OMass Technologies | $103M | 27 Apr 2022 | Oxford, England, United Kingdom | ||
Resolution Therapeutics | $13M | 05 Apr 2022 | London, England, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Purespring Therapeutics | 09 Oct 2024 | London, England, United Kingdom | |||
Resolution Therapeutics | 03 Oct 2024 | London, England, United Kingdom | |||
Yellowstone Biosciences | $22M | 20 Jun 2024 | Oxford, Oxfordshire, United Kingdom | ||
Beacon Therapeutics | $170M | 03 Jun 2024 | London, England, United Kingdom | ||
Beacon Therapeutics | $131M | 12 Jun 2023 | London, England, United Kingdom | ||
Mosaic Therapeutics | $28M | 04 Apr 2023 | Cambridge, Cambridgeshire, United Kingdom | ||
SwanBio Therapeutics | $56M | 18 May 2022 | Lower Merion Township, Pennsylvania, United States | ||
OMass Technologies | $103M | 27 Apr 2022 | Oxford, England, United Kingdom | ||
Resolution Therapeutics | $13M | 05 Apr 2022 | London, England, United Kingdom |